The optimum use of intravenous immunoglobulin for prophylaxis of opportunistic infection in HIV-infected adults

BioDrugs

Volumn 10, Issue 4, 1998, Pages 265-273

  Kiehl, Michael G ^a,b   Müller, Carsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; VIRUS INFECTION;

EID: 0031738320     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810040-00002     Document Type: Article

References (65)

1. Shearer GM, Salahuddin SZ, Markham PD, et al. Prospective study of cytotoxic T lymphocyte responses to influenza and antibodies to human T lymphotropic virus- III in homosexual men. Selective loss of an influenza-specific, human leukocyte antigen-restricted cytotoxic T lymphocyte response in human T lymphotropic virus-III positive individuals with symptoms of acquired immunodeficiency syndrome and in a patient with acquired immunodeficiency syndrome. J Clin Invest 1985; 76: 1699-704
2. Lane HC, Depper JM, Greene WC, et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985; 313: 79-84
3. Calabrese LH. Autoimmune manifestations of human immunodeficiency virus (HIV) infection. Clin Lab Med 1988; 8: 269-79
4. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267: 1798-805
5. Simonds RJ, Hughes WT, Feinberg J, et al. Preventing Pneumocystis carinii pneumonia in person infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: S44-8
6. Chaisson RE, Keruly J, Richman DD, et al. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992; 152: 2009-13
7. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Myrobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-91
8. Nightingale SD. Rifabutin prophylaxis against Mycobacterium avium complex infection. Lancet 1995; 345: 265
9. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828-33
10. Juranek DD. Cryptosporidiosis: source of infection and guidelines for prevention. Clin Infect Dis 1995; 21: S57-61
11. McNeil MM, Ampel NM. Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis 1995; 21: S111-3
12. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995; 21: S12-31
13. Lane HC, Fauci AS. Immunologic abnormalities in the aquired immunodeficiency syndrome. Annu Rev Immunol 1985; 3: 477-500
14. Förster R, Schweigard G, Johann S, et al. Abnormal expression of the B-cell homing chemokine receptor BLR1 during the progression of acquired immunodeficiency syndrome. Blood 1997; 90: 520-5
15. Peng XX, Wainberg MA, Tao Y, et al. Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1. Clin Diagn Lab Immunol 1996; 1: 128-31
16. Chess Q, Daniels J, North E, et al. Serum immunoglobulin elevations in the acquired immunodeficiency syndrome (AIDS): IgG, IgA, IgM, and IgD. Diagn Immunol 1984; 2: 148-53
17. Yap PL, Todd AA, Williams PE, et al. Use of intravenous immunoglobulin in acquired immune deficiency syndrome. Cancer 1991; 68: 1440-50
18. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309: 453-8
19. van der Lelie J, Lange JMA, Vos JJE, et al. Autoimmunity against blood cells in human immunodeficiency virus infection. Br J Haematol 1987; 67: 755-63
20. Pahwa S, Pahwa R, Saxinger C, et al. Influence of the human T-lymphotropic virus/lymphadenopathy- associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci USA 1985; 82: 8198-202
21. Kopelman RG, Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84: 82-8
22. Ditzel HJ, Barbas SM, Barbas CE, et al. The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1994; 91: 3710-4
23. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1179-86
24. Salama A, Lohmeyer J, Seeger W, et al. High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS). Ann Hematol 1991; 63: 77-8
25. Mueller C, Kunkel S, Bauer R. Relationsship of autoantibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely associated with CD4 cell depletion. Immunology 1993; 79: 248-54
26. Walsh CM, Nardi MA, Karpatkin S. On the mechansim of thrombocytopenic purpura in sexally active homosexual men. N Engl J Med 1984; 311: 635-41
27. Landonio G, Galli M, Nosari A, et al. HIV-related severe thrombocytopenia in intravenous drug users: prevalence, response to therapy in a medium-term follow-up, and pathogenetic evaluation. AIDS 1990; 4: 29-34
28. Freter CE. Acquired immunodeficiency syndrome-associated lymphomas. Monogr Natl Cancer Inst 1990; 45-54
29. Polsky B, Gold JWM, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 393-8
30. Keller DW, Breiman RF. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl. 1: S77-83
31. Crow ME. Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients. Am J Health Syst Pharm 1995; 52: 803-11
32. Jason J, Murphy J, Sleeper LA, et al. Hemophilia Growth and Development Study Group. Immune and serologic profiles of HIV-infected and noninfected hemophilic children and adolescents. Am J Hematol 1994; 46: 29-35
33. Forsyth BW. Primary care of children with HIV infection. Curr Opin Pediatr 1995; 7: 502-12
34. Calvelli TA, Rubinstein A. Intravenous gamma-globulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis 1986; 5: S207-10
35. Gupta A, Novick BE, Rubinstein A. Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment. Am J Dis Child 1986; 140: 143-6
36. Yap PL, Williams PE. Immunoglobulin preparations for HIV-infected patients. Vox Sang 1988; 55: 65-74
37. Schaad UB, Gianella Borradori A, Perret B, et al. Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection. Eur J Pediatr 1988; 147: 300-3
38. Hague RA, Yap PL, Mok JY, et al. Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment. Arch Dis Child 1989; 64: 1146-50
39. The International Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73-80
40. Mofenson LM, Moye J, Bethel J, et al. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 × 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. JAMA 1992; 268: 483-8
41. Heitmann K, Stutzer H, Bauer P. Comments on the statistical evaluation of the ARC-IVIG Study. Vox Sang 1990; 59 Suppl. 1: 59-60
42. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994; 331: 1181-7
43. Silverman BA, Rubinstein A. Serum lactate dehydrogenase levels in adults and children with the aquired immune deficiency syndrome (AIDS) and AIDS-releated complex: Possible indicator of B-cell proliferation and disease activity: effects of intravenous gammaglobulin on enzym levels. Am J Med 1985; 78: 728-36
44. Krueger GR, Ramon A, Degenhardt S, et al. Cellular immunologic parameters in HIV-positive patients with AIDS-related complex and intravenous immunoglobulin therapy. Vox Sang 1990; 59 Suppl. 1: 30-7
45. Mofenson LM, Moye JJ. Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection. Pediatr Res 1993; 33: 380-7
46. Mofenson LM, Bethel J, Moye J, et al. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993; 6: 1103-13
47. Olopoenia L, Young M, White D, et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 1997; 89: 543-7
48. Mofenson LM, Moye J, Korelitz J, et al. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13: 477-84
49. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995; 21 Suppl. 1: S32-43
50. Schrappe-Bacher M, Rasokat H, Bauer P, et al. High-dose intravenous immunoglobulins in HIV-1-infected adults with AIDS-related complex and Walter-Reed 5. Vox Sang 1990: 59 Suppl. 1: 3-14
51. Brunkhorst U, Sturner M, Willers H, et al. Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection. A randomized clinical study. Infection 1990; 18: 86-90
52. Williams PE, Thompson C, Yap PL, et al. Controlled Study of intravenous IgG therapy for HIV-infected adults with recurrent bacterial infections. Vox Sang 1991; 60: 126-7
53. Saint Marc T, Touraine JL, Berra N. Beneficial effects of intravenous immunoglobulins in AIDS. Lancet 1992; 340: 1347-7
54. Jablonowski H, Sander O, Willers R, et al. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Invest 1994; 72: 220-4
55. Kiehl MG, Stoll R, Broder M, et al. A controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection. Arch Intern Med 1996; 156: 2545-50
56. De Simone C, Cirelli A, Catania S, et al. Immunopharmacological activity of intravenous gammaglobulins in AIDS and ARC patients. J Immunol Immunopharmacol 1989; 9: 8-11
57. Rogna S, Puppo F, Stagnaro R, et al. Plasmaexchange plus immunoglobulins for treatment of hypergammaglobulinaemic patients with AIDS and AIDS-related complex (ARC). Cancer Detect Prev 1988; 12: 273-6
58. Centers for Disease Control. Update on acquired immune deficiency syndrome (AIDS) - United States. MMWR Morb Mortal Wkly Rep 1982; 31: 507-14
59. Centers for Disease Control. Classification system for human T-lymphortopic virus III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986; 35: 334-9
60. Redfield RR, Wright DC, Tramont EC. The Walter-Reed classification in the follow-up of HIV-infection. N Engl J Med 1986; 315: 1355-6
61. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definiton for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1994; 41 (RR-17): 1-19
62. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996; 276: 146-54
63. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
64. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
65. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Update recommendations of the International AIDS Society-USA panel. JAMA 1997; 277: 1962-9